Trans-ferulic acid had the greatest hit rate against the protein targets IRS-1 and Akt, which may act as adjuvant drugs to tackle T2DM with lesser or no complications and need to be validated by wet-lab investigations. The gene discussed is IRS1; the disease is type 2 diabetes mellitus.